ClinicalTrials.gg
TerminatedNCT00086346Updated Apr 28, 2010Results posted

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

A Phase 3 interventional study of Sirolimus (Rapamune) and Cyclosporine or Tacrolimus in Liver Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated at 42 sites in 12 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Liver
  • Transplant
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than 13 years (age greater than 18 years as required by some local regulations).
  • Receiving therapy with calcineurin inhibitors (CI) +/- +/- antimetabolite.
  • 6 to 144 months after orthotopic liver transplantation.
  • values ≥40 mL/min and ≤90mL/min at screening

Exclusion criteria

Exclusion Criteria:

  • History of nonhepatic transplantation
  • Evidence of systemic infection (sepsis, bacteremia, pneumonia etc).
  • Known or suspected \< 5 years before random assignment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
607 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Sirolimus (Rapamune)

  • Active comparator
    B

    Drug: Cyclosporine or Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)

    GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is \>90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.

    Time frame: Baseline and 12 months

  2. Patient and Graft Survival

    Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.

    Time frame: 12 months

Secondary outcomes

  1. Number of Patients With a Biopsy Confirmed Acute Rejection

    Overall event rate is determined as yes or no.

    Time frame: 12 months

  2. Mean Serum Creatinine

    Observed mean values for serum creatinine.

    Time frame: 12 months

07

Results

Posted Sep 7, 2009

Participant flow

Patients were recruited October 2002 to November 2006.

Randomization
Participant flow — Randomization
MilestoneSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Started393214
Completed389210
Not completed44
Withdrew: Did not receive test article44
Patients Dosed With Test Article
Participant flow — Patients Dosed With Test Article
MilestoneSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Started389210
Completed249187
Not completed14023
Withdrew: Adverse event9411
Withdrew: Lost to follow-up13
Withdrew: Nonmedical event73
Withdrew: Withdrawal by subject163
Withdrew: Protocol violation113
Withdrew: Lack of efficacy110

Outcome measures

PrimaryChange From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is \>90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.

Time frame:
Baseline and 12 months
Reported as:
Mean · mL/min
Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)
mL/minSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)-4.45 ± 1.12-3.07 ± 1.36
Statistical analysis
  • Sirolimus (SRL) Conversion vs Calcineurin Inhibitors (CNI) Continuation · Rank ANCOVA · p = 0.342
SecondaryNumber of Patients With a Biopsy Confirmed Acute Rejection

Overall event rate is determined as yes or no.

Time frame:
12 months
Reported as:
Number · patients
Number of Patients With a Biopsy Confirmed Acute Rejection
patientsSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Yes4613
No347201
Statistical analysis
  • Sirolimus (SRL) Conversion vs Calcineurin Inhibitors (CNI) Continuation · Cochran-Mantel-Haenszel · p = 0.017
SecondaryMean Serum Creatinine

Observed mean values for serum creatinine.

Time frame:
12 months
Reported as:
Mean · µmol/L
Mean Serum Creatinine
µmol/LSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Mean Serum Creatinine119.0 ± 38.9122.4 ± 31.5
Statistical analysis
  • Sirolimus (SRL) Conversion vs Calcineurin Inhibitors (CNI) Continuation · 1 way ANOVA, two sided · p = >0.05
PrimaryPatient and Graft Survival

Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.

Time frame:
12 months
Reported as:
Number · patients
Patient and Graft Survival
patientsSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Graft survival367202
Graft loss (total)2612
Graft loss: Pure (with retransplant)00
Graft loss: Death133
Graft loss: Incomplete data139
Statistical analysis
  • Sirolimus (SRL) Conversion vs Calcineurin Inhibitors (CNI) Continuation · Mean difference (net): -1.2 · 95% CI -5.2 to 2.8Weighted difference in percentage of graft loss: (CNI% minus SRL%); negative values are favorable to CNI group

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus (SRL) Conversion——386/389 (99.2%)
Calcineurin Inhibitors (CNI) Continuation——201/210 (95.7%)
Most frequent serious events
Showing 10 of 210
Most frequent serious events
EventSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
Skin carcinomaSkin and subcutaneous tissue disorders14/38919/210
PneumoniaRespiratory, thoracic and mediastinal disorders17/3894/210
FeverGeneral disorders16/3898/210
DiarrheaGastrointestinal disorders16/3895/210
Liver function tests abnormalGastrointestinal disorders15/3893/210
Local reaction to procedureGeneral disorders13/3893/210
AnemiaBlood and lymphatic system disorders12/3894/210
Cerebrovascular accidentVascular disorders1/3896/210
HerniaGeneral disorders11/3893/210
Abdominal painGeneral disorders10/3894/210
Most frequent other events
Showing 10 of 72
Most frequent other events
EventSirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) Continuation
HyperlipemiaMetabolism and nutrition disorders159/38920/210
DiarrheaGastrointestinal disorders136/38938/210
Peripheral edemaMetabolism and nutrition disorders127/38929/210
RashSkin and subcutaneous tissue disorders111/38916/210
HypercholesteremiaMetabolism and nutrition disorders110/3899/210
StomatitisGastrointestinal disorders103/3894/210
InfectionGeneral disorders97/38943/210
AnemiaBlood and lymphatic system disorders94/38919/210
HeadacheGeneral disorders84/38923/210
AstheniaGeneral disorders79/38928/210

Baseline characteristics

Age Continuous
Age Continuous(years)Sirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) ContinuationTotal
Median57.0 (23.0 to 76.0)56.5 (21.0 to 73.0)57.0 (21.0 to 76.0)
Sex: Female, Male
Sex: Female, Male(Participants)Sirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) ContinuationTotal
Female12264186.0
Male271150421.0
Mean serum creatinine levels
Mean serum creatinine levels(μmol/L)Sirolimus (SRL) ConversionCalcineurin Inhibitors (CNI) ContinuationTotal
Mean122.9 ± 32.3125.2 ± 31.9123.7 ± 32.2
08

Study locations

42 sites
  • San Francisco, California 94143-0780, United States
  • Tampa, Florida 33606, United States
  • New Orleans, Louisiana 70121, United States
  • Detroit, Michigan 48202, United States
  • Rochester, Minnesota 55905, United States
  • Omaha, Nebraska 68198-3285, United States
  • New York, New York 10029, United States
  • Rochester, New York 14642-8410, United States
  • Cleveland, Ohio 44195, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Gent, 9000, Belgium
  • Edmonton, Alberta T6G 2B7, Canada
  • London, Ontario N6A 5A5, Canada
  • Toronto, Ontario M5G 2C4, Canada
  • Prague, 14021, Czech Republic
  • Clichy, 92118, France
  • Lyon, 69437, France
  • Nice, 06200, France
  • Paris, 75679, France
  • Rennes, 35033, France
  • Villejuif, 94800, France
  • Berlin, 13353, Germany
  • Hamburg, 20251, Germany
  • München, 81377, Germany
  • Bologna, Italy
  • Milano, 20122, Italy
  • Padova, 35128, Italy
  • Leiden, 2300, Netherlands
  • Coimbra, 3049, Portugal
  • Lisboa, 1069-166, Portugal
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08907, Spain
  • Madrid, 28034, Spain
  • Pamplona, 31008, Spain
  • Santiago de Compostela, 15706, Spain
  • Valencia, 46009, Spain
  • Bern, CH-3010, Switzerland
  • Zürich, CH-8091, Switzerland
  • Birmingham, B15 2TH, United Kingdom
  • Edinburgh, EH16 4SA, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2004
First posted
Jul 2, 2004
Start
Dec 2002
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Sep 7, 2009
Last update
Apr 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00086346
First posted
Jul 2, 2004
Start date
Dec 2002
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Sep 7, 2009
Last update
Apr 28, 2010

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Italy, decresg@wyeth.com
Trial Manager
principal investigator · For Germany, MedInfoDEU@wyeth.com
Trial Manager
principal investigator · For Belgium, trials-BEL@wyeth.com
Trial Manager
principal investigator · For Czech Republic, WPPGCLI@wyeth.com
Trial Manager
principal investigator · For Netherlands, trials-NL@wyeth.com
Trial Manager
principal investigator · For Switzerland, med@wyeth.com
Trial Manager
principal investigator · For UK, ukmedinfo@wyeth.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Cyclosporine · Tacrolimus

Start the discussion